Physician profile

Jay M Barbakoff

Pulmonary Disease · Port Jefferson, NY

NPI 1003994260

$2,307.88

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $530.26 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $302.96 2019-2020
Astrazeneca Pharmaceuticals LP $269.13 2019-2020
Sunovion Pharmaceuticals INC. $186.95 2019-2020
Genentech USA, INC. $136.40 2019
Novartis Pharmaceuticals Corporation $130.58 2019-2020
Mylan Specialty L.P. $97.78 2019-2020
Electromed, INC. $80.25 2019
Genzyme Corporation $76.27 2019
Merck Sharp & Dohme LLC $70.97 2019-2020
Regeneron Healthcare Solutions, INC. $70.71 2019-2020
Advanced Respiratory, INC $66.92 2020
Actelion Pharmaceuticals US, INC. $62.35 2019-2020
Philips North America LLC $37.94 2019-2020
Pfizer INC. $37.05 2019
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Mallinckrodt Hospital Products INC. $32.44 2020
La Jolla Pharmaceutical Company $30.41 2020
Tetraphase Pharmaceuticals, INC. $20.42 2019
Apria Healthcare LLC $19.52 2021
Chiesi USA, INC. $19.00 2019
Olympus America INC. $15.08 2020
Janssen Pharmaceuticals, INC $14.49 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jay M Barbakoff

$2,307.88

in general payments reported 2019-2025

Years
2019-2021
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/466/jay-m-barbakoff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.